Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model

Journal for ImmunoTherapy of Cancer

Airi Harui¹  Michael D Roth¹ 

[1] Division of Pulmonary & Critical Care, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles 90095-1690, CA, USA

关键词: Humanized;    Tumor infiltrating lymphocyte;    Human prostate cancer;    NOD/SCID/IL-2Rγnull;   

Others  :  1204150
DOI  :  10.1186/s40425-015-0056-2

 received in 2015-01-16, accepted in 2015-03-06,  发布年份 2015

【 摘 要 】

Background

The complex interactions that occur between human tumors, tumor infiltrating lymphocytes (TIL) and the systemic immune system are likely to define critical factors in the host response to cancer. While conventional animal models have identified an array of potential anti-tumor therapies, mouse models often fail to translate into effective human treatments. Our goal is to establish a humanized tumor model as a more effective pre-clinical platform for understanding and manipulating TIL.

Methods

The immune system in NOD/SCID/IL-2Rγnull (NSG) mice was reconstituted by the co-administration of human peripheral blood lymphocytes (PBL) or subsets (CD4+ or CD8+) and autologous human dendritic cells (DC), and animals simultaneously challenged by implanting human prostate cancer cells (PC3 line). Tumor growth was evaluated over time and the phenotype of recovered splenocytes and TIL characterized by flow cytometry and immunohistochemistry (IHC). Serum levels of circulating cytokines and chemokines were also assessed.

Results

A tumor-bearing huPBL-NSG model was established in which human leukocytes reconstituted secondary lymphoid organs and promoted the accumulation of TIL. These TIL exhibited a unique phenotype when compared to splenocytes with a predominance of CD8+ T cells that exhibited increased expression of CD69, CD56, and an effector memory phenotype. TIL from huPBL-NSG animals closely matched the features of TIL recovered from primary human prostate cancers. Human cytokines were readily detectible in the serum and exhibited a different profile in animals implanted with PBL alone, tumor alone, and those reconstituted with both. Immune reconstitution slowed but could not eliminate tumor growth and this effect required the presence of CD4+ T cell help.

Conclusions

Simultaneous implantation of human PBL, DC and tumor results in a huPBL-NSG model that recapitulates the development of human TIL and allows an assessment of tumor and immune system interaction that cannot be carried out in humans. Furthermore, the capacity to manipulate individual features and cell populations provides an opportunity for hypothesis testing and outcome monitoring in a humanized system that may be more relevant than conventional mouse models.

【 授权许可】

   
2015 Roth and Harui; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood). 2011; 236(5):567-79.
• [2]Vesalainen S, Lipponen P, Talja M, SyrjQnen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994; 30A(12):1797-803.
• [3]Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014; 257(1):56-71.
• [4]Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M et al.. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A. 2012; 109(16):6187-92.
• [5]Zonari E, Pucci F, Saini M, Mazzieri R, Politi LS, Gentner B et al.. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood. 2013; 122(2):243-52.
• [6]Boissonnas A, Licata F, Poupel L, Jacquelin S, Fetler L, Krumeich S et al.. CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. Neoplasia. 2013; 15(1):85-94.
• [7]Ganesan AP, Johansson M, Ruffell B, Yagui-Beltrán A, Lau J, Jablons DM et al.. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol. 2013; 191(4):2009-17.
• [8]Sharma RK, Chheda Z, Jala VR, Haribabu B. Expression of leukotriene B4 receptor-1 on CD8+ T cells is required for their migration into tumors to elicit effective antitumor immunity. J Immunol. 2013; 191(6):3462-70.
• [9]Reddy S, Piccione D, Takita H, Bankert RB. Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency. Cancer Res. 1987; 47(9):2456-60.
• [10]Williams SS, Chen FA, Kida H, Yokata S, Miya K, Kato M et al.. Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J Immunol. 1996; 156(5):1908-15.
• [11]Bankert RB, Egilmez NK, Hess SD. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. 2001; 22(7):386-93.
• [12]Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, Bernstein SH et al.. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J Immunol. 2003; 170(1):400-12.
• [13]Broderick L, Yokota SJ, Reineke J, Mathiowitz E, Stewart CC, Barcos M et al.. Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-γ, and eradicate tumor cells. J Immunol. 2005; 174(2):898-906.
• [14]Simpson-Abelson MR, Sonnenberg GF, Takita H, Yokota SJ, Conway TF, Kelleher RJ et al.. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol. 2008; 180(10):7009-18.
• [15]Harui A, Kiertscher SM, Roth MD. Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation. J Neuroimmune Pharmacol. 2011; 6(1):148-57.
• [16]Engram JC, Cervasi B, Borghans JA, Klatt NR, Gordon SN, Chahroudi A et al.. Lineage-specific T-cell reconstitution following in vivo CD4+ and CD8+ lymphocyte depletion in nonhuman primates. Blood. 2010; 116(5):748-58.
• [17]Gorantla S, Makarov E, Finke-Dwyer J, Gebhart CL, Domm W, Dewhurst S et al.. CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol. 2010; 184(12):7082-91.
• [18]Kitchen SG, Korin YD, Roth MD, Landay A, Zack JA. Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol. 1998; 72(11):9054-60.
• [19]Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G et al.. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain (null) mice. Blood. 2005; 106(5):1565-73.
• [20]Kanaji N, Tadokoro A, Susaki K, Yokokura S, Ohmichi K, Haba R et al.. Higher susceptibility of NOD/LtSz-scid Il2rg (−/−) NSG mice to xenotransplanted lung cancer cell lines. Cancer Manag Res. 2014; 6:431-6.
• [21]Yu CI, Gallegos M, Marches F, Zurawski G, Ramilo O, García-Sastre A et al.. Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines. Blood. 2008; 112(9):3671-8.
• [22]Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I et al.. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005; 201(8):1257-68.
• [23]Joncker NT, Marloie MA, Chernysheva A, Lonchay C, Cuff S, Klijanienko J et al.. Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int J Cancer. 2006; 118(5):1205-14.
• [24]Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B et al.. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol. 1997; 109(3):501-9.
• [25]Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE et al.. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013; 109(10):2705-13.
• [26]Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al.. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65.
• [27]Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ et al.. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013; 24(7):1813-21.
• [28]Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Liénard D, Lejeune F et al.. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004; 64(8):2865-73.
• [29]Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006; 86(3):231-45.
• [30]Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM et al.. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007; 13(23):6947-58.
• [31]Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol Med. 2000; 6(6):465-79.
• [32]Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001; 7(10):1118-22.
• [33]Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA. Cutting edge: tumor-specific CD8 T cells infiltrating prostatic tumors Are induced to become suppressor cells. J Immunol. 2009; 183:4848-52.
• [34]Ye J, Ma C, Wang F, Hsueh EC, Toth K, Huang Y et al.. Specific recruitment of γδ regulatory T cells in human breast cancer. Cancer Res. 2013; 73(20):6137-48.
• [35]Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D, Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003; 97(5):1211-6.
• [36]Tazaki E, Shimizu N, Tanaka R, Yoshizumi M, Kamma H, Imoto S et al.. Serum cytokine profiles in patients with prostate carcinoma. Exp Ther Med. 2011; 2(5):887-91.
• [37]Gonzalez L, Strbo N, Podack ER. Humanized mice: novel model for studying mechanisms of human immune-based therapies. Immunol Res. 2013; 57(1–3):326-34.
• [38]Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL, Greiner DL. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc. 2014; 2014(7):694-708.
• [39]Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, Männel DN et al.. Humanized tumor mice–a new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer. 2011; 129(9):2194-206.
• [40]Kiertscher SM, Roth MD. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol. 1996; 59(2):208-18.